NEW YORK, December 30, 2025, 12:33 ET — Regular session
- Edgewise Therapeutics shares were up 0.2% in midday trading, after an SEC Form 144 disclosed insider sales.
- The filing reported 116,665 shares sold on Dec. 26 with an aggregate value of about $3.04 million.
- Biotech stocks were lower broadly, keeping attention on the next clinical and financial checkpoints.
Edgewise Therapeutics shares were up 0.2% at $24.68 as of 12:18 p.m. ET on Tuesday, after a Form 144 filing showed company officer Robert Michael Carruthers sold 116,665 shares worth about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92.
The disclosure matters because Edgewise is a development-stage biotech, where trading often centers on clinical milestones and cash runway rather than product sales. Insider transactions can draw outsized attention after sharp moves, even when the dollar amounts are modest.
Biotech stocks also lagged, with the iShares Nasdaq Biotechnology ETF down 1.4% and the SPDR S&P Biotech ETF down 1.6%, while the tech-heavy Invesco QQQ was little changed.
Form 144 is a notice insiders file in connection with sales made under Rule 144, which governs resales of shares held by company affiliates and other controlled stock. Traders often scan the filings for timing and size, looking for clues on near-term supply.
Based on the filing figures, the sale worked out to roughly $26 per share and about 0.11% of the company’s roughly 105.9 million shares outstanding. The filing said the shares were acquired through option exercises under a company plan.
The transaction comes days after Edgewise highlighted progress in its Phase 2 CIRRUS-HCM study of EDG-7500 in hypertrophic cardiomyopathy, a condition in which the heart muscle thickens and can impair blood flow. In that Dec. 24 update, CEO Kevin Koch said, “I’m especially pleased with EDG-7500’s safety profile to date.” PR Newswire
Edgewise has emphasized left ventricular ejection fraction (LVEF) — a measure of how much blood the heart pumps with each beat — as a key safety marker. The company said it has not seen “clinically meaningful” drops in LVEF in the interim Part D safety update, and it is aiming for a full 12-week Part D readout in the second quarter of 2026.
Investors are also tracking how EDG-7500 will stack up against marketed and emerging hypertrophic cardiomyopathy drugs in the cardiac myosin inhibitor class, which regulators have tied to heart-failure risk and monitoring requirements.
Edgewise describes itself as a muscle-disease biopharmaceutical company developing therapies for muscular dystrophies and serious cardiac conditions.
Cash remains a key watch item for traders in pre-revenue drug developers. In its most recent quarterly update, the company said cash, cash equivalents and marketable securities were about $563.3 million as of Sept. 30.
The next clear catalyst on the calendar is the company’s next quarterly results, which tracking services expect around early March, though companies can shift dates.
